168 related articles for article (PubMed ID: 38607586)
1. Dual-loss of PBRM1 and RAD51 identifies hyper-sensitive subset patients to immunotherapy in clear cell renal cell carcinoma.
Xu Z; Jiang W; Liu L; Qiu Y; Wang J; Dai S; Guo J; Xu J
Cancer Immunol Immunother; 2024 Apr; 73(5):95. PubMed ID: 38607586
[TBL] [Abstract][Full Text] [Related]
2. Loss of PBRM1 and BAP1 expression is less common in non-clear cell renal cell carcinoma than in clear cell renal cell carcinoma.
Ho TH; Kapur P; Joseph RW; Serie DJ; Eckel-Passow JE; Parasramka M; Cheville JC; Wu KJ; Frenkel E; Rakheja D; Stefanius K; Brugarolas J; Parker AS
Urol Oncol; 2015 Jan; 33(1):23.e9-23.e14. PubMed ID: 25465300
[TBL] [Abstract][Full Text] [Related]
3. CCL5-dependent mast cell infiltration into the tumor microenvironment in clear cell renal cell carcinoma patients.
Liu T; Xia Q; Zhang H; Wang Z; Yang W; Gu X; Hou T; Chen Y; Pei X; Zhu G; He D; Li L; Xu S
Aging (Albany NY); 2020 Nov; 12(21):21809-21836. PubMed ID: 33177244
[TBL] [Abstract][Full Text] [Related]
4. PBRM1 mutation and WDR72 expression as potential combinatorial biomarker for predicting the response to Nivolumab in patients with ccRCC: a tumor marker prognostic study.
Chang Q; Sun J; Zhao S; Li L; Zhang N; Yan L; Fan Y; Liu J
Aging (Albany NY); 2023 Nov; 15(23):13753-13775. PubMed ID: 38048211
[TBL] [Abstract][Full Text] [Related]
5. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma.
Miao D; Margolis CA; Gao W; Voss MH; Li W; Martini DJ; Norton C; Bossé D; Wankowicz SM; Cullen D; Horak C; Wind-Rotolo M; Tracy A; Giannakis M; Hodi FS; Drake CG; Ball MW; Allaf ME; Snyder A; Hellmann MD; Ho T; Motzer RJ; Signoretti S; Kaelin WG; Choueiri TK; Van Allen EM
Science; 2018 Feb; 359(6377):801-806. PubMed ID: 29301960
[TBL] [Abstract][Full Text] [Related]
6. Development and validation of a PBRM1-associated immune prognostic model for clear cell renal cell carcinoma.
Chen J; Yao C; Qiao N; Ge Y; Li J; Lin Y; Yao S
Cancer Med; 2021 Oct; 10(19):6590-6609. PubMed ID: 34535962
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive Multi-Omics Identification of Interferon-γ Response Characteristics Reveals That RBCK1 Regulates the Immunosuppressive Microenvironment of Renal Cell Carcinoma.
Xu W; Tao J; Zhu W; Liu W; Anwaier A; Tian X; Su J; Shi G; Huang H; Wei G; Li C; Qu Y; Zhang H; Ye D
Front Immunol; 2021; 12():734646. PubMed ID: 34795663
[TBL] [Abstract][Full Text] [Related]
8. NKG2A
Qiu Y; Liu L; Jiang W; Xu Z; Wang J; Dai S; Guo J; Xu J
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38262706
[TBL] [Abstract][Full Text] [Related]
9. A pan-cancer analysis of PBAF complex mutations and their association with immunotherapy response.
Hakimi AA; Attalla K; DiNatale RG; Ostrovnaya I; Flynn J; Blum KA; Ged Y; Hoen D; Kendall SM; Reznik E; Bowman A; Hwee J; Fong CJ; Kuo F; Voss MH; Chan TA; Motzer RJ
Nat Commun; 2020 Aug; 11(1):4168. PubMed ID: 32820162
[TBL] [Abstract][Full Text] [Related]
10.
Klümper N; Ralser DJ; Zarbl R; Schlack K; Schrader AJ; Rehlinghaus M; Hoffmann MJ; Niegisch G; Uhlig A; Trojan L; Steinestel J; Steinestel K; Wirtz RM; Sikic D; Eckstein M; Kristiansen G; Toma M; Hölzel M; Ritter M; Strieth S; Ellinger J; Dietrich D
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34446578
[TBL] [Abstract][Full Text] [Related]
11. Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation.
Kapur P; Peña-Llopis S; Christie A; Zhrebker L; Pavía-Jiménez A; Rathmell WK; Xie XJ; Brugarolas J
Lancet Oncol; 2013 Feb; 14(2):159-167. PubMed ID: 23333114
[TBL] [Abstract][Full Text] [Related]
12. An integrative genomics approach for identifying novel functional consequences of PBRM1 truncated mutations in clear cell renal cell carcinoma (ccRCC).
Wang Y; Guo X; Bray MJ; Ding Z; Zhao Z
BMC Genomics; 2016 Aug; 17 Suppl 7(Suppl 7):515. PubMed ID: 27556922
[TBL] [Abstract][Full Text] [Related]
13. PBRM1 Regulates the Expression of Genes Involved in Metabolism and Cell Adhesion in Renal Clear Cell Carcinoma.
Chowdhury B; Porter EG; Stewart JC; Ferreira CR; Schipma MJ; Dykhuizen EC
PLoS One; 2016; 11(4):e0153718. PubMed ID: 27100670
[TBL] [Abstract][Full Text] [Related]
14. The Significance of PARP1 as a biomarker for Predicting the Response to PD-L1 Blockade in Patients with PBRM1-mutated Clear Cell Renal Cell Carcinoma.
Hagiwara M; Fushimi A; Matsumoto K; Oya M
Eur Urol; 2022 Feb; 81(2):145-148. PubMed ID: 34627641
[TBL] [Abstract][Full Text] [Related]
15. PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma.
Liu XD; Kong W; Peterson CB; McGrail DJ; Hoang A; Zhang X; Lam T; Pilie PG; Zhu H; Beckermann KE; Haake SM; Isgandrova S; Martinez-Moczygemba M; Sahni N; Tannir NM; Lin SY; Rathmell WK; Jonasch E
Nat Commun; 2020 May; 11(1):2135. PubMed ID: 32358509
[TBL] [Abstract][Full Text] [Related]
16. BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies.
Piva F; Santoni M; Matrana MR; Satti S; Giulietti M; Occhipinti G; Massari F; Cheng L; Lopez-Beltran A; Scarpelli M; Principato G; Cascinu S; Montironi R
Expert Rev Mol Diagn; 2015; 15(9):1201-10. PubMed ID: 26166446
[TBL] [Abstract][Full Text] [Related]
17. Loss of PBRM1 expression is associated with renal cell carcinoma progression.
Pawłowski R; Mühl SM; Sulser T; Krek W; Moch H; Schraml P
Int J Cancer; 2013 Jan; 132(2):E11-7. PubMed ID: 22949125
[TBL] [Abstract][Full Text] [Related]
18. Commentary on "Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation." Kapur P, Peña-Llopis S, Christie A, Zhrebker L, Pavía-Jiménez A, Rathmell WK, Xie XJ, Brugarolas J. Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX. Lancet Oncol 2013; 14(2):159-67. [Epub 2013 Jan 16]. doi: 10.1016/S1470-2045(12)70584-3.
Boorjian S
Urol Oncol; 2014 Aug; 32(6):934-5. PubMed ID: 25087671
[TBL] [Abstract][Full Text] [Related]
19. Immune inactivation by CD47 expression predicts clinical outcomes and therapeutic responses in clear cell renal cell carcinoma patients.
Jiang W; Zeng H; Liu Z; Jin K; Hu B; Chang Y; Liu L; Zhu Y; Xu L; Wang Z; Guo J; Xu J
Urol Oncol; 2022 Apr; 40(4):166.e15-166.e25. PubMed ID: 34998671
[TBL] [Abstract][Full Text] [Related]
20. Immune-Associated Gene Signatures Serve as a Promising Biomarker of Immunotherapeutic Prognosis for Renal Clear Cell Carcinoma.
Wang Q; Tang H; Luo X; Chen J; Zhang X; Li X; Li Y; Chen Y; Xu Y; Han S
Front Immunol; 2022; 13():890150. PubMed ID: 35686121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
